Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James Larkin

Showing results (391-400 of 419) with videos related to

Pageof 42
Sort By:
European Journal of Cancer (Oxford, England : 1990)|February 25, 2024
Prognostic and predictive value of non-steroidal anti-inflammatory drugs in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanomaOliver John Kennedy, Nina Glassee, Michal Kicinski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 26, 2022
Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)Jeffrey S Weber, Dirk Schadendorf, Michele Del Vecchio, et al.
The Lancet. Oncology|April 15, 2021
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trialAndrew Bottomley, Corneel Coens, Justyna Mierzynska, et al.
Journal of Translational Medicine|June 5, 2013
Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012"Paolo A Ascierto, Antonio M Grimaldi, Nicolas Acquavella, et al.
Nature Communications|March 20, 2015
Recurrent chromosomal gains and heterogeneous driver mutations characterise papillary renal cancer evolutionMichal Kovac, Carolina Navas, Stuart Horswell, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 14, 2014
First light of the Gemini Planet imagerBruce Macintosh, James R Graham, Patrick Ingraham, et al.
European Journal of Heart Failure|October 23, 2020
Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the Translational Research Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)Rudolf A de Boer, Jean-Sébastien Hulot, Carlo Gabriele Tocchetti, et al.
Cell|April 17, 2018
Tracking Cancer Evolution Reveals Constrained Routes to Metastases: TRACERx RenalSamra Turajlic, Hang Xu, Kevin Litchfield, et al.
Journal for Immunotherapy of Cancer|May 4, 2026
Discontinuation of combo immunotherapy and outcome of patients with melanoma brain metastasesMario Mandalà, Monica F Chen, Ryan J Sullivan, et al.
Cell|April 17, 2018
Timing the Landmark Events in the Evolution of Clear Cell Renal Cell Cancer: TRACERx RenalThomas J Mitchell, Samra Turajlic, Andrew Rowan, et al.
Pageof 42

Showing results (391-400 of 419) with videos related to

Sort By:
Pageof 42
European Journal of Cancer (Oxford, England : 1990)|February 25, 2024
Prognostic and predictive value of non-steroidal anti-inflammatory drugs in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanomaOliver John Kennedy, Nina Glassee, Michal Kicinski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 26, 2022
Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)Jeffrey S Weber, Dirk Schadendorf, Michele Del Vecchio, et al.
The Lancet. Oncology|April 15, 2021
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trialAndrew Bottomley, Corneel Coens, Justyna Mierzynska, et al.
Journal of Translational Medicine|June 5, 2013
Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012"Paolo A Ascierto, Antonio M Grimaldi, Nicolas Acquavella, et al.
Nature Communications|March 20, 2015
Recurrent chromosomal gains and heterogeneous driver mutations characterise papillary renal cancer evolutionMichal Kovac, Carolina Navas, Stuart Horswell, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 14, 2014
First light of the Gemini Planet imagerBruce Macintosh, James R Graham, Patrick Ingraham, et al.
European Journal of Heart Failure|October 23, 2020
Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the Translational Research Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)Rudolf A de Boer, Jean-Sébastien Hulot, Carlo Gabriele Tocchetti, et al.
Cell|April 17, 2018
Tracking Cancer Evolution Reveals Constrained Routes to Metastases: TRACERx RenalSamra Turajlic, Hang Xu, Kevin Litchfield, et al.
Journal for Immunotherapy of Cancer|May 4, 2026
Discontinuation of combo immunotherapy and outcome of patients with melanoma brain metastasesMario Mandalà, Monica F Chen, Ryan J Sullivan, et al.
Cell|April 17, 2018
Timing the Landmark Events in the Evolution of Clear Cell Renal Cell Cancer: TRACERx RenalThomas J Mitchell, Samra Turajlic, Andrew Rowan, et al.
Pageof 42